KRAS mutations were detected in 16.7% of cases, consistent with the literature reporting KRAS as a recurrent alteration in 10–20% of cervical adenocarcinomas, particularly in HPV-negative and gastric-type tumors [39,40]. The gene discussed is KRAS; the disease is cervical adenocarcinoma.